Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept in Lung Transplantation
NCT03388008Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2019
- Primary completion
- Aug 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of belatacept in lung transplant rejection, antibody mediated rejection (AMR), sponsored by Washington University School of Medicine. Started Dec 2019; status: completed.
02
Drugs
belatacept
03
Conditions
lung transplant rejectionantibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT03388008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03388008.